Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal

 
• By Kevin Grogan

The Danish dermatology specialist could be hitting the acquisition trail again soon having taken an option to buy BridgeBio's PellePharm and its skin cancer drug patidegib in a deal that could be worth $760m.

Young man recovering healing at home after plastic surgery nose
Gorlin leads to the formation of multiple basal cell carcinomas, often on the face • Source: Shutterstock

More from Dermatological

More from Therapy Areas